Optimizing Antibody-Drug Conjugate Safety: Pharmacist Strategies for Grading, Monitoring, and Supportive Care

Program Description

Antibody-drug conjugates (ADCs) are an important class of targeted anticancer therapies that link a monoclonal antibody to a cytotoxic payload, enabling delivery of treatment to selected tumor cells while expanding their use across hematologic malignancies and solid tumors. As ADC adoption has expanded, so have the complexities of safe use, especially because toxicity is shaped by target biology, linker stability, payload class, treatment context, and whether an ADC is used alone or in combination with other agents. Oncology pharmacists must understand how to differentiate ADC-related toxicities by mechanism and presentation, including gastrointestinal, hematologic, pulmonary, neurologic, and other systemic adverse events, as well as how to distinguish acute from delayed events and separate ADC toxicity from overlapping toxicities caused by prior or concurrent therapy. This webinar will emphasize evidence-based monitoring, Common Terminology Criteria for Adverse Events (CTCAE)–based grading, and escalation strategies that support early identification and prevention of severe adverse events, treatment interruptions, and unnecessary discontinuation. It will also highlight how pharmacists can build practical workflows for baseline and longitudinal monitoring, coordinate multidisciplinary supportive care, and use standardized documentation and decision support to improve consistency across settings. Because ADC toxicities can be complex, overlapping, and sometimes high risk, this webinar will emphasize strategies for oncology pharmacists to anticipate toxicity patterns, guide patient counseling, optimize supportive care, and ensure timely intervention to maintain safety and treatment delivery.

Target audience: Oncology Pharmacists
Type of activity: Application
Release date: October 29, 2026
Expiration date: October 29, 2027
Learner level: Intermediate, Advanced
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Differentiate antibody-drug conjugate (ADC)–related toxicities based on payload class, target biology, and treatment context, including considerations for combination therapy and overlapping adverse events
• Apply evidence-informed monitoring and escalation strategies for ADC-associated toxicities to oncology pharmacy workflows to support early detection, risk mitigation, and interdisciplinary communication
• Exercise supportive care and patient counseling strategies for ADC therapy, including prophylaxis, care coordination, and education on toxicity prevention and early warning signs

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This application-based activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-26-338-H05-P. The activity is available for CE credit through October 29, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Megan May, PharmD, BCOP, FHOPA, FAPO, has the following relevant financial relationships with ineligible companies to disclose:

Speakers Bureau: AbbVie, Amgen, AstraZeneca, Genmab, and Pharmacosmos

The staff of Pharmacy Times Continuing Education™ have no relevant financial relationships with ineligible companies.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

AI Disclosure

Artificial intelligence (AI) tools may have been used to support the development of this continuing education activity, such as for data organization or slide design. All AI-assisted content was reviewed and verified by qualified staff, faculty, or planners before release to ensure accuracy, balance, and freedom from commercial bias. Where applicable, specific details regarding the AI tool, its purpose, and the review process are disclosed within the activity materials. The accredited provider retains full responsibility for the activity’s content, accuracy, balance, and independence.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact: [email protected]
Privacy Policy and Terms of Use Information: www.pharmacytimes.org/terms